Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was the recipient of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 4,220,460 shares, a decline of 35.4% from the August 31st total of 6,532,907 shares. Based on an average daily volume of 856,492 shares, the days-to-cover ratio is presently 4.9 days. Currently, 5.9% of the company’s stock are short sold.

Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) opened at 2.65 on Wednesday. The stock’s market capitalization is $224.07 million. Catalyst Pharmaceuticals has a 52 week low of $0.94 and a 52 week high of $3.20. The firm’s 50-day moving average price is $2.61 and its 200 day moving average price is $2.38.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Analysts expect that Catalyst Pharmaceuticals will post ($0.23) earnings per share for the current year.

In related news, insider Patrick J. Mcenany purchased 20,000 shares of the stock in a transaction dated Tuesday, September 5th. The stock was purchased at an average price of $2.58 per share, with a total value of $51,600.00. Following the transaction, the insider now directly owns 4,471,026 shares in the company, valued at $11,535,247.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 8.79% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter worth $111,000. New York State Common Retirement Fund purchased a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $114,000. Oxford Asset Management lifted its holdings in shares of Catalyst Pharmaceuticals by 138.1% during the 1st quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 34,181 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Catalyst Pharmaceuticals by 3.6% during the 1st quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 2,404 shares during the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $149,000. 40.15% of the stock is currently owned by institutional investors and hedge funds.

CPRX has been the subject of a number of analyst reports. SunTrust Banks, Inc. restated a “buy” rating and set a $5.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Tuesday, September 5th. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, Zacks Investment Research downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $4.90.

ILLEGAL ACTIVITY WARNING: “Short Interest in Catalyst Pharmaceuticals, Inc. (CPRX) Drops By 35.4%” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/short-interest-in-catalyst-pharmaceuticals-inc-cprx-drops-by-35-4/1606333.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.